CAMBRIDGE, Mass.–(BUSINESS WIRE)–Cellarity, a life sciences company founded by Flagship Pioneering to code and simulate human biology to reinvent the way we create medicines, today announced the expansion of its leadership team with three appointments keys. As Chief Scientific Officer, Laurens Kruidenier, Ph.D., will lead the continued evolution of Cellarity’s platform and pipeline and oversee cross-functional integration across all aspects of computation, drug creation and optimization. . As Chief People Officer, Anna O’Driscoll will lead the development of human resources and talent development strategies to enable Cellarity’s rapid growth and make the company a preferred place to work for talent. As Senior Vice President and Head of Data and Software Engineering, Parul Doshi will lead the development of a state-of-the-art and scalable data infrastructure to support the entire drug creation and development process. .
“We are building a transformative company and bringing together a strong team of people with proven track records to make things happen,” said Fabrice Chouraqui, Ph.D., CEO of Cellarity and CEO-Partner at Flagship Pioneering. “Laurens is not only an exceptional translational scientist, with experience and successes that advance primary research into clinical-stage programs, he is also a team and business builder, helping to integrate and make evolve drug discovery platforms.”
Dr Chouraqui continued, “Anna brings deep experience in developing talent and leadership in the biotech industry, and is known for her passion for positively impacting the employee experience. Parul not only brings a extensive expertise in data infrastructure across the entire pharmaceutical value chain, from preclinical and clinical operations to technology operations and commercialization, but also practical expertise in software engineering. I am delighted that these great leaders have joined us at this pivotal moment as Cellarity grows our team, advances key programs and develops a pipeline of important new therapies.
Cellarity has developed unique capabilities to code biology and computationally model the changes that occur between health and disease to design breakthrough medicines. Cellarity’s transformative approach to drug creation goes beyond an individual molecular target to understand the complex biological web of cellular changes that underlie disease onset and progression. Built at the confluence of systems biology, single-cell data and machine learning, the Cellarity platform leverages a more comprehensive view of cell biology to create drugs with purpose. Since all disease originates from a disorder at the cellular level, Cellarity’s approach can be applied to virtually any disease and uncovers new biology and treatments that are unlikely to be found through discovery. target-based.
“Despite the enormous strides made by the industry in advancing medical treatments, most diseases have no cures, and there are thousands of conditions that lack treatments,” said Dr Kruidenier. “I am impressed with Cellarity’s drug creation engine, which goes beyond the single target and encompasses the full complexity of human disease. I look forward to working with the team to realize the truly transformative nature of the Cellarity platform and to advance new drugs in various therapeutic areas into the clinic to address a wide range of patient needs.
Laurens Kruidenier, Ph.D., Scientific Director
Dr. Kruidenier has over 25 years of experience in frontier research, both in academia and in the life sciences industry and a track record of success in drug discovery and development, leading research programs towards clinical studies and integrating teams and technologies. for growth and scale. Prior to joining Cellarity, Dr. Kruidenier was Chief Scientific Officer (CSO) at Prometheus Biosciences, a precision medicine company in the area of immune-mediated diseases. At Prometheus, he helped grow the company from an early-stage Cedars-Sinai-spin-out startup to a Nasdaq-listed platform-focused holding company with three active Phase 2 clinical trials. , he served as Vice President of Discovery at Second Genome, where he was responsible for a portfolio of microbiome programs and Head of Gastrointestinal Immunology Research at Takeda Pharmaceuticals, where he was responsible for development global discovery research and commercial development strategy in inflammatory bowel disease. Earlier in his career, Dr. Kruidenier held various positions in different discovery units at GlaxoSmithKline, where he led preclinical teams and drug discovery projects in immuno-inflammation, epigenetics and protein degradation. He completed his post-doctoral training at the University of London and holds an M.Sc. in medical biology from the University of Utrecht and a Ph.D. in mucosal immunology from Leiden University. His research has resulted in multiple publications in leading scientific journals, including Nature.
Anna O’Driscoll, Director of Human Resources
Ms. O’Driscoll has over a decade of human resources experience and was most recently vice president of human resources at Alnylam Pharmaceuticals, where she held positions spanning R&D, sales, corporate functions, learning and development and employee relations as Alnylam. has grown from a research organization to a leading biotechnology company. Prior to Alnylam, she was responsible for talent strategy and process at Shire and the human resources leadership development program at Johnson & Johnson. Ms. O’Driscoll holds an MBA from the Institute of Chartered Financial Analysts and a BA in Marketing and Languages from Dublin City University.
Parul Doshi, Senior Vice President, Head of Data and Software Engineering
Ms. Doshi has over twenty years of experience in information technology (IT) and software engineering and was most recently head of IT and digital for Takeda’s Vaccines division. She has spent the past 16 years at Takeda, in roles of increasing seniority across multiple divisions of the company. In particular, she led the computer programs to launch the NINLARO oncology products® and ALUNBRIG® as well as the consolidation of the Vaccines Business Unit in Cambridge, Massachusetts and the integration of ARIAD Pharmaceuticals after the acquisition. Prior to Takeda, Ms. Doshi worked as a developer at Patni Computer Systems, serving large companies such as Fidelity Investments and LEGO.®. Ms. Doshi holds an MBA in Information Technology and Finance from Savitribai Phule Pune University and a BSc in Economics and Applied Statistics from the University of Rajasthan.
About the winery
Cellarity’s mission is to fundamentally transform the way medicines are created through the development of the first complete digital battery. Founded by Flagship Pioneering in 2017, Cellarity has developed unique capabilities combining high-resolution data, single cell technologies and machine learning to code biology, model interventions and purposefully design breakthrough medicines. By focusing on the cellular changes that underlie disease rather than a single target, Cellarity’s approach uncovers new biology and treatments and applies to a wide range of disease areas. The company currently has ongoing programs in the areas of metabolic disease, hematology, immuno-oncology and respiratory disease. The company raised $123m in a Series B funding round with contributions from funds and accounts managed by Blackrock, Baupost Group, Banque Pictet on behalf of their clients and eight other investors alongside of Flagship Pioneering. For more information, visit www.cellarity.com.
About Flagship Pioneering
Flagship Pioneering designs, creates, resources and grows best-in-class bioplatform companies to transform human health and sustainability. Since its launch in 2000, the company has, through its Flagship Labs unit, applied its unique hypothesis-driven innovation process to create and foster more than 100 scientific projects, generating a total value of more than 140 billions of dollars. To date, Flagship has deployed more than $2.6 billion in capital for the creation and growth of its pioneering companies, as well as more than $19 billion in follow-on investments from other institutions. The current flagship ecosystem comprises 42 transformative companies, including Axcella Health (Nasdaq: AXLA), Codiak BioSciences (Nasdaq: CDAK) Denali Therapeutics (Nasdaq: DNLI), Evelo Biosciences (Nasdaq: EVLO), Foghorn Therapeutics (Nasdaq: FHTX), Indigo Ag, Kaleido Biosciences (Nasdaq: KLDO), Moderna (Nasdaq: MRNA), Omega Therapeutics (Nasdaq: OMGA), Rubius Therapeutics (Nasdaq: RUBY), Sana Biotechnology (Nasdaq: SANA), Seres Therapeutics (Nasdaq: MCRB) and Sigilon Therapeutics (Nasdaq: SGTX).